Research Topics
| Guido J TricotSummaryAffiliation: University of Utah Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilizationG Tricot
University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bone Marrow Transplant 45:63-8. 2010..The safety profile of plerixafor in all patients was consistent with previous reports...
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot
University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
Haematologica 93:1739-42. 2008..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 135:158-64. 2006..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 111:1309-17. 2008..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells...
Results of autologous stem cell transplant in multiple myeloma patients with renal failureA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:822-9. 2001..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation...
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor aloneK R Desikan
The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 112:242-7. 2001..Patients with high tumour burden, i.e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment...
What is the significance of molecular remission in multiple myeloma?Guido J Tricot
Clinical Research in the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Clin Adv Hematol Oncol 5:91-5. 2007..The time to disease progression of such patients appears to be significantly longer compared to that of patients not achieving a molecular CR...
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsA Badros
Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
Blood 97:2574-9. 2001..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure...
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:600-7. 2001..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...
Thrombotic events in patients with cancer receiving antiangiogenesis agentsMaurizio Zangari
University of Utah, Division of Hematology, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
J Clin Oncol 27:4865-73. 2009..Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy...
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsM Zangari
Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Blood Coagul Fibrinolysis 13:187-92. 2002..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
Results of high-dose treatment with autologous stem cell support in patients with multiple myelomaA Fassas
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 38:231-42. 2001..Special emphasis is placed on the safety and efficacy of transplant in elderly patients and in those with impaired renal function, who are usually excluded from the most effective therapy...
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 98:492-4. 2001..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM...
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vectorR B Batchu
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Hum Gene Ther 14:1333-45. 2003..We present evidence that the DC phenotype is unaltered after transduction and that more than 85% of DCs express NY-ESO-1, which secrete approximately 40 ng of GM-CSF per 10(6) DCs...
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplantC K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Bone Marrow Transplant 33:823-8. 2004..05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course...
Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantationC K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Bone Marrow Transplant 37:511-5. 2006....
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodesT Mahfouz
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, 72205, USA
J Clin Oncol 23:7857-63. 2005..CONCLUSION: In patients with MM, FDG-PET is a useful tool for diagnosing and managing infections even in the setting of severe immunosuppression...
Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservationS Szmania
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cytotherapy 7:374-84. 2005..Cryopreservation did not interfere with DC activity, allowed time for rigorous quality control (QC) and flexible scheduling of intranodal vaccination, and reduced the time to prepare multiple vaccines...
Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantationA C Sherman
Behavioral Medicine, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Bone Marrow Transplant 33:955-62. 2004..Results highlight the importance of early screening...
Transplantation as salvage therapy for high-risk patients with myeloma in relapseC-K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bone Marrow Transplant 30:873-8. 2002..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors...
Clinical activity of arsenic trioxide for the treatment of multiple myelomaN C Munshi
University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
Leukemia 16:1835-7. 2002..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM...
Thalidomide in the management of multiple myelomaB Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
Semin Oncol 28:577-82. 2001..Several trials are currently underway at the Arkansas Myeloma and Transplantation Research Center to determine the clinical benefit of adding thalidomide to post-transplant salvage therapy and in the upfront management of patients...
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyM Zangari
Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 98:1614-5. 2001....
Thalidomide in the management of multiple myelomaB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Semin Hematol 38:250-9. 2001..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated...
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myelomaJ R Sawyer
Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 112:167-74. 2001..The chromosome instability identified here demonstrates that the loss of 8p can occur by multiple whole-arm translocations, indicating a new pathway for the loss of a specific chromosome region in MM...
Research Grants
- Gene expression profiling vs MRD assessment in MyelomaGuido Tricot; Fiscal Year: 2006..These findings can serve as a model for treatment approaches in other chronic lymphoproliferative and myeloproliferative malignancies, which exhibit a similar disease progression. ..
- Gene expression profiling vs MRD assessment in MyelomaGuido J Tricot; Fiscal Year: 2010..These findings can serve as a model for treatment approaches in other chronic lymphoproliferative and myeloproliferative malignancies, which exhibit a similar disease progression. ..
